Skip to main content
SpringerLink
Log in

Nouvelles approches thérapeutiques dans le cancer du sein HER2 positif

New therapeutic approaches in HER2 breast cancer

  • Mise au Point / Update
  • Published:
Oncologie

Résumé

Depuis plus de dix ans, les thérapeutiques ciblées anti-HER2 ont permis une amélioration révolutionnaire du pronostic des cancers du sein HER2 positifs, faisant de ce traitement la colonne vertébrale de la prise en charge. Malgré le bénéfice, des phénomènes d’échappement apparaissent au cours du traitement et face à ce constat, de nouvelles stratégies thérapeutiques ont été développées et ont prouvé leurs efficacités. Cette synthèse détaille la prise en charge thérapeutique du cancer du sein métastatique HER2 positif, son évolution thérapeutique et les études cliniques en cours.

Abstract

For over 10 years, HER2-directed therapy has shown a revolutionary improvement in the prognosis of breast cancer, making such treatment the backbone of the management. Despite the benefit, a resistance process could appear during the treatment and novel therapeutics strategies have been developed and have proved their efficacy. This article describes the therapeutic management of HER2 positive metastatic breast cancer, its therapeutic evolution, and the ongoing clinical trials.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Références

  1. Pagani O, Senkus E, Wood W, et al. (2010) International guidelines for management of metastatic breast cancer: can metastatic breast cancer be cured? J Natl Cancer Inst 102: 456–63

    Article  PubMed  PubMed Central  Google Scholar 

  2. Justo N, Wilking N, Jonsson B, et al. (2013) A review of breast cancer care and outcomes in Latin America. Oncologist 18: 248–56

    Article  PubMed  PubMed Central  Google Scholar 

  3. Dawood S, Broglio K, Buzdar AU, et al. (2010) Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review. J Clin Oncol 28: 92–8

    Article  CAS  PubMed  Google Scholar 

  4. Goldhirsch A, Wood WC, Coates AS, et al. (2011) Strategies for subtypes — dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer. Ann Oncol 22: 1736–47

    CAS  PubMed  Google Scholar 

  5. Vaz-Luis I, Winer EP, Lin NU (2013) Human epidermal growth factor receptor-2-positive breast cancer: does estrogen receptor status define two distinct subtypes? Ann Oncol 24: 283–91

    Article  CAS  PubMed  Google Scholar 

  6. Marty M, Cognetti F, Maraninchi D, et al. (2005) Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as firstline treatment: the M77001 study group. J Clin Oncol 23: 4265–74

    Article  CAS  PubMed  Google Scholar 

  7. Slamon DJ, Leyland-Jones B, Shak S, et al. (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344: 783–92

    Article  CAS  PubMed  Google Scholar 

  8. Romond EH, Jeong JH, Rastogi P, et al. (2012) Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 30: 3792–9

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Perez EA, Romond EH, Suman VJ, et al. (2011) Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. J Clin Oncol 29: 3366–73

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Gianni L, Dafni U, Gelber RD, et al. (2011) Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomized controlled trial. Lancet Oncol 12: 236–44

    Article  CAS  PubMed  Google Scholar 

  11. Pivot X, Romieu G, Debled M, et al. (2013) 6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomized phase 3 trial. Lancet Oncol 14: 741–8

    Article  CAS  PubMed  Google Scholar 

  12. Staaf J, Jonsson G, Ringner M, et al. (2011) Landscape of somatic allelic imbalances and copy number alterations in HER2-amplified breast cancer. Breast Cancer Res 13: R129

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Ismael G, Hegg R, Muehlbauer S, et al. (2012) Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomized trial. Lancet Oncol 13: 869–78

    Article  CAS  PubMed  Google Scholar 

  14. Valero V, Forbes J, Pegram MD, et al. (2011) Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active therapeutic regimens. J Clin Oncol 29: 149–56

    Article  CAS  PubMed  Google Scholar 

  15. Kaufman B, Mackey JR, Clemens MR, et al. (2009) Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study. J Clin Oncol 27: 5529–37

    Article  CAS  PubMed  Google Scholar 

  16. Johnston S, Pippen J Jr., Pivot X, et al. (2009) Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol 27: 5538–46

    Article  CAS  PubMed  Google Scholar 

  17. von Minckwitz G, Schwedler K, Schmidt M, et al. (2011) Trastuzumab beyond progression: overall survival analysis of the GBG 26/BIG 3-05 phase III study in HER2-positive breast cancer. Eur J Cancer 47: 2273–81

    Article  Google Scholar 

  18. Geyer CE, Forster J, Lindquist D, et al. (2006) Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355: 2733–43

    Article  CAS  PubMed  Google Scholar 

  19. Gelmon FB, Kaufman B, Huntsman D, et al. (2015) Chapman and Wendy Parulekar. Open-label phase III randomized controlled trial comparing taxane-based chemotherapy (Tax) with lapatinib (L) or trastuzumab (T) as first-line therapy for women with HER2+ metastatic breast cancer: Interim analysis (IA) of NCIC CTG MA.31/GSK EGF 108919. J Clin Oncol (Epub ahead of print)

    Google Scholar 

  20. Pivot X, Manikhas A, Zurawski B, et al. (2015) CEREBEL (EGF111438): an open label randomized phase III study comparing lapatinib plus capeciatbine vs trastuzumab plus capecitabine in patients with HER2+ metastatic breast cancer. J Clin Oncol (Epub ahead of print)

    Google Scholar 

  21. Baselga J, Bradbury I, Eidtmann H, et al. (2012) Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomized, open-label, multicentre, phase 3 trial. Lancet 379: 633–40

    Article  CAS  PubMed  Google Scholar 

  22. Untch M, Loibl S, Bischoff J, et al. (2012) Lapatinib versus trastuzumab in combination with neoadjuvant anthracyclinetaxane-based chemotherapy (GeparQuinto, GBG 44): a randomized phase 3 trial. Lancet Oncol 13: 135–44

    Article  CAS  PubMed  Google Scholar 

  23. Robidoux A TG, Rastogi P, et al. (2012) Evaluation of lapatinib as a component of neoadjuvant therapy for HER2+ operable breast cancer: NSABP protocol B-41. J Clin Oncol ASCO Annual Meeting Proceedings 2012; Vol 30

    Google Scholar 

  24. Blackwell KL, Burstein HJ, Storniolo AM, et al. (2010) Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol 28: 1124–30

    Article  CAS  PubMed  Google Scholar 

  25. Rimawi MF, Osborne CK (2012) Breast Cancer: blocking both driver and escape pathways improves outcomes. Nat Rev Clin Oncol 9: 133–4

    Article  CAS  PubMed  Google Scholar 

  26. Goltsov A, Faratian D, Langdon SP, et al. (2012) Features of the reversible sensitivity-resistance transition in PI3K/PTEN/AKT signalling network after HER2 inhibition. Cell Signal 24: 493–504

    Article  CAS  PubMed  Google Scholar 

  27. Ghosh R, Narasanna A, Wang SE, et al. (2011) Trastuzumab has preferential activity against breast cancers driven by HER2 homodimers. Cancer Res 71: 1871–82

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Takada M, Higuchi T, Tozuka K, et al. (2013) Alterations of the genes involved in the PI3K and estrogen-receptor pathways influence outcome in human epidermal growth factor receptor 2-positive and hormone receptor-positive breast cancer patients treated with trastuzumab-containing neoadjuvant chemotherapy. BMC Cancer 13: 241

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Scheuer W, Friess T, Burtscher H, et al. (2009) Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models. Cancer Res 69: 9330–6

    Article  CAS  PubMed  Google Scholar 

  30. Agus DB, Gordon MS, Taylor C, et al. (2005) Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer. J Clin Oncol 23: 2534–43

    Article  CAS  PubMed  Google Scholar 

  31. Yamamoto N, Yamada Y, Fujiwara Y, et al. (2009) Phase I and pharmacokinetic study of HER2-targeted rhuMAb 2C4 (pertuzumab, RO4368451) in Japanese patients with solid tumors. Jpn J Clin Oncol 39: 260–6

    Article  PubMed  PubMed Central  Google Scholar 

  32. Attard G, Kitzen J, Blagden SP, et al. (2007) A phase Ib study of pertuzumab, a recombinant humanised antibody to HER2, and docetaxel in patients with advanced solid tumours. Br J Cancer 97: 1338–43

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Albanell J, Montagut C, Jones ET, et al. (2008) A phase I study of the safety and pharmacokinetics of the combination of pertuzumab (rhuMab 2C4) and capecitabine in patients with advanced solid tumors. Clin Cancer Res 14: 2726–31

    Article  CAS  PubMed  Google Scholar 

  34. Persson M, Gedda L, Lundqvist H, et al. (2007) [177Lu]pertuzumab: experimental therapy of HER-2-expressing xenografts. Cancer Res 67: 326–31

    Article  CAS  PubMed  Google Scholar 

  35. Ng CM, Lum BL, Gimenez V, et al. (2006) Rationale for fixed dosing of pertuzumab in cancer patients based on population pharmacokinetic analysis. Pharm Res 23: 1275–84

    Article  CAS  PubMed  Google Scholar 

  36. Gianni L, Llado A, Bianchi G, et al. (2010) Open-label, phase II, multicenter, randomized study of the efficacy and safety of two dose levels of pertuzumab, a human epidermal growth factor receptor 2 dimerization inhibitor, in patients with human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 28: 1131–7

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Agus DB, Sweeney CJ, Morris MJ, et al. (2007) Efficacy and safety of single-agent pertuzumab (rhuMAb 2C4), a human epidermal growth factor receptor dimerization inhibitor, in castrationresistant prostate cancer after progression from taxane-based therapy. J Clin Oncol 25: 675–81

    Article  CAS  PubMed  Google Scholar 

  38. Herbst RS, Davies AM, Natale RB, et al. (2007) Efficacy and safety of single-agent pertuzumab, a human epidermal receptor dimerization inhibitor, in patients with non small cell lung cancer. Clin Cancer Res 13: 6175–81

    Article  CAS  PubMed  Google Scholar 

  39. Gordon MS, Matei D, Aghajanian C, et al. (2006) Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status. J Clin Oncol 24: 4324–32

    Article  CAS  PubMed  Google Scholar 

  40. de Bono JS, Bellmunt J, Attard G, et al. (2007) Open-label phase II study evaluating the efficacy and safety of two doses of pertuzumab in castrate chemotherapy-naive patients with hormonerefractory prostate cancer. J Clin Oncol 25: 257–62

    Article  PubMed  Google Scholar 

  41. Gianni L, Pienkowski T, Im YH, et al. (2012) Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NEOSPHERE): a randomized multicentre, open-label, phase 2 trial. Lancet Oncol 13: 25–32

    Article  CAS  PubMed  Google Scholar 

  42. Schneeweiss A, Chia S, Hickish T, et al. (2013) Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol 24: 2278–84

    Article  CAS  PubMed  Google Scholar 

  43. Baselga J, Gelmon KA, Verma S, et al. (2010) Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. J Clin Oncol 28: 1138–44

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Adams CW, Allison DE, Flagella K, et al. (2006) Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab. Cancer Immunol Immunother 55: 717–27

    Article  CAS  PubMed  Google Scholar 

  45. Cortes J, Fumoleau P, Bianchi GV, et al. (2012) Pertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab: activity and tolerability in patients with advanced human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 30: 1594–600

    Article  CAS  PubMed  Google Scholar 

  46. Baselga J, Cortes J, Kim SB, et al. (2012) Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 366: 109–19

    Article  CAS  PubMed  Google Scholar 

  47. Swaim SM, Baselga J, Kim SB, et al. (2015) pertuzumab, trastuzumab and docetaxel in HER2 positive metastatic breast cancer. NEJM 372: 724–34

    Article  Google Scholar 

  48. Swain SM, Ewer MS, Cortes J, et al. (2013) Cardiac tolerability of pertuzumab plus trastuzumab plus docetaxel in patients with HER2-positive metastatic breast cancer in CLEOPATRA: a randomized, double-blind, placebo-controlled phase III study. Oncologist 18: 257–64

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Guiu S, Mouret Reynier MA, Toure M, Coudert B (2013) Predictive factors of response in HER2-positive breast cancer treated by neoadjuvant therapy. J Oncol 854121

    Google Scholar 

  50. Baselga J, Cortés J, Im SA, et al. (2012) Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in HER2-positive, first-line metastatic breast cancer (MBC). 35 th SABCS 2012; Abstract S5-1

    Google Scholar 

  51. Goncalves A, Tredan O, Villanueva C, Dumontet C (2012) Antibody-drug conjugates in oncology: from the concept to trastuzumab emtansine (T-DM1)]. Bull Cancer 99: 1183–91

    CAS  PubMed  Google Scholar 

  52. Girish S, Gupta M, Wang B, et al. (2012) Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody-drug conjugate in development for the treatment of HER2-positive cancer. Cancer Chemother Pharmacol 69: 1229–40

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Lo Russo PM, Weiss D, Guardino E, et al. (2011) Trastuzumab emtansine: a unique antibody-drug conjugate in development for human epidermal growth factor receptor 2-positive cancer. Clin Cancer Res 17: 6437–47

    Article  Google Scholar 

  54. Erickson HK, Lewis Phillips GD, Leipold DD, et al. (2012) The effect of different linkers on target cell catabolism and pharmacokinetics/ pharmacodynamics of trastuzumab maytansinoid conjugates. Mol Cancer Ther 11: 1133–42

    Article  CAS  PubMed  Google Scholar 

  55. Shen BQ, Bumbaca D, Saad O, et al. (2012) Catabolic fate and pharmacokinetic characterization of trastuzumab emtansine (T-DM1): an emphasis on preclinical and clinical catabolism. Curr Drug Metab 13: 901–10

    Article  CAS  PubMed  Google Scholar 

  56. Krop IE, Beeram M, Modi S, et al. (2010) Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer. J Clin Oncol 28: 2698–704

    Article  CAS  PubMed  Google Scholar 

  57. Beeram M, Krop IE, Burris HA, et al. (2012) A phase 1 study of weekly dosing of trastuzumab emtansine (T-DM1) in patients with advanced human epidermal growth factor 2-positive breast cancer. Cancer 118: 5733–40

    Article  CAS  PubMed  Google Scholar 

  58. Burris HA 3rd, Rugo HS, Vukelja SJ, et al. (2011) Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. J Clin Oncol 29: 398–405

    Article  CAS  PubMed  Google Scholar 

  59. Krop IE, Lo Russo P, Miller KD, et al. (2012) A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine. J Clin Oncol 30: 3234–41

    Article  CAS  PubMed  Google Scholar 

  60. Hurvitz SA, Dirix L, Kocsis J, et al. (2013) Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol 31: 1157–63

    Article  CAS  PubMed  Google Scholar 

  61. Verma S, Miles D, Gianni L, et al. (2012) Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 367: 1783–91

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  62. Bender BC, Schaedeli-Stark F, Koch R, et al. (2012) A population pharmacokinetic/pharmacodynamic model of thrombocytopenia characterizing the effect of trastuzumab emtansine (T-DM1) on platelet counts in patients with HER2-positive metastatic breast cancer. Cancer Chemother Pharmacol 70: 591–601

    Article  CAS  PubMed  Google Scholar 

  63. Krop IE, Kim SB, Gonzalez-Martin A, et al. (2014) Trastuzumab emtansine versus treatment of physician’s choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomized open label phase 3 trial. Lancet Oncol 15: 689–99

    Article  CAS  PubMed  Google Scholar 

  64. Lu D, Burris HA, 3rd, Wang B, et al. (2012) Drug interaction potential of trastuzumab emtansine (T-DM1) combined with pertuzumab in patients with HER2-positive metastatic breast cancer. Curr Drug Metab 13: 911–22

    Article  CAS  PubMed  Google Scholar 

  65. Yamashita-Kashima Y, Shu S, Harada N, Fujimoto-Ouchi K (2013) Enhanced antitumor activity of trastuzumab emtansine (T-DM1) in combination with pertuzumab in a HER2-positive gastric cancer model. Oncol Rep 30: 1087–93

    CAS  PubMed  Google Scholar 

  66. Piccart-Gebhart M, Holmes AP, Baselga J, et al. (2014) First results from the phase III ALTTO trial (BIG 2-06; NCCTG [Alliance] N063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (T →L), or their combination (T+L) in the adjuvant treatment of HER2-positive early breast cancer (EBC). J Clinic Oncol 32: 55. LBA 4

    Article  Google Scholar 

  67. André F, O’Reagan R, Ozguroglu M, et al. (2014) Everolimus for women with trastuzumab-resistant HER2 positive, advanced breast cancer (BOLERO-3): a randomized double blind placebocontrolled phase 3 trial. Lancet Oncol 15: 580–91

    Article  PubMed  Google Scholar 

  68. Hurvitz S, André F, Jiang Z, et al. (2014) HER2+ Advanced Breast Cancer: BOLERO-1. SABCS 2014. Abstract S6-01

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Service d’oncologie médicale, CHU de Besançon, F-25030, Besançon cedex, France

    C. Villanueva, J. Malvestiti, L. Chaigneau, L. Cals & X. Pivot

  2. URM 1098 Inserm/UFC/EFS, CHU de Besançon, F-25030, Besançon cedex, France

    X. Pivot

Authors
  1. C. Villanueva
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. Malvestiti
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. L. Chaigneau
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. L. Cals
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. X. Pivot
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to C. Villanueva.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Villanueva, C., Malvestiti, J., Chaigneau, L. et al. Nouvelles approches thérapeutiques dans le cancer du sein HER2 positif. Oncologie 19, 108–119 (2017). https://doi.org/10.1007/s10269-015-2534-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10269-015-2534-z

Mots clés

Keywords

Search

Navigation